For the first time, researchers at Umeå University and Lund University have estimated the risk of developing various types of prostate cancer for men with the disease in the family.
Men with brothers who have had prostate cancer run twice as high a risk of being diagnosed themselves in comparison to the general population.
This according to a study published in the Journal of the National Cancer Institute.
"It's well known that men with prostate cancer in the family have a higher risk of the disease," says Pär Stattin, researcher at the Department of Surgical and Perioperative Sciences and principal investigator of Prostate Cancer data Base Sweden (PCBaSe), which was the basis for the study.
"Prostate cancer is often a rather indolent disease with favourable prognosis that often doesn't require treatment but there are also aggressive types that can be mortal. The ability to differ between these types is therefore important. Up until now, there has been no knowledge about the absolute magnitudes of these risks."
In PCBaSe, Swedish researchers in Umeå and Lund have studied the prostate cancer risk in over 50,000 men in Sweden whose brothers and fathers had prostate cancer.
The results show men with one brother with prostate cancer had:
The National Guidelines for prostate cancer states that men with two or more close relatives with prostate cancer should be recommended for prostate screenings starting at between 40 to 50 years of age.
The check-ups involve regular PSA testing and potentially also examinations of the prostate gland.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.